Form 4: Mycotopia Therapies CEO Acquires 20 Million Shares in Lieu of Cash Compensation

Mycotopia Therapies CEO, Benjamin Kaplan, acquired 20 million shares of common stock in lieu of cash compensation for director's fees.

Summary

• Benjamin Kaplan, CEO of Mycotopia Therapies, acquired 20,000,000 shares of common stock on December 13, 2024.
• The shares were received in lieu of cash payment for a portion of his director's fees.
• The price per share was $0.014.
• Following the transaction, Kaplan's total holdings increased to 20,250,000 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as the CEO is taking shares instead of cash, which is a positive sign for the company's cash position. However, the low share price may be a concern.

Positives

• The acquisition demonstrates the CEO's confidence in the company's future.
• The use of shares instead of cash preserves the company's cash reserves.

Management Comments

• The shares were received in lieu of cash for a portion of the filer's director's fees.

Industry Context

This type of transaction, where executives receive stock in lieu of cash compensation, is not uncommon in the biotech and pharmaceutical industries, especially for companies that are still in the development phase and looking to conserve cash.

Comparison to Industry Standards

• Many biotech companies use stock-based compensation to align management interests with shareholder value, similar to companies like Amyris and Novavax who have used stock options and grants as part of their compensation packages.
• The price of $0.014 per share is very low, which may indicate the company is in an early stage or has a low valuation compared to more established companies in the sector such as Jazz Pharmaceuticals or GW Pharmaceuticals.

Stakeholder Impact

• Shareholders may view this as a positive sign of management's commitment to the company.
• The company's cash reserves are preserved by issuing shares instead of cash.

Key Dates

Keywords

Mycotopia Therapies, TPIA, Benjamin Kaplan, CEO, stock acquisition, director fees, insider trading, Form 4